Home / Resource Library / Outcomes following transition from ibrutinib to zanubrutinib in patients with Waldenstrom macroglobulinemia from ASPENOutcomes following transition from ibrutinib to zanubrutinib in patients with Waldenstrom macroglobulinemia from ASPEN